Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities

Abstract Background Advanced age and underlying comorbidities are associated with greater rates of recurrence in patients with Clostridioides difficile infection (CDI). Reducing the likelihood of recurrence through treatment with an antimicrobial followed by a microbiota replacement therapy can decrease the burden of this infection and improve patient outcomes. We report the efficacy and safety of RBX2660, a microbiota-based live biotherapeutic, in older adults with recurrent CDI, grouped by comorbidities. Methods In this post hoc subgroup analysis of the PUNCH CD3 trial, we assessed outcomes in older adults (age ≥65 years) grouped by Charlson Comorbidity Index severity scores at screening (moderate [3–4] and severe [≥5]) and by the presence of underlying cardiac, renal, or gastrointestinal disorders. Results RBX2660 treatment success rates in older adults with comorbidities were consistent across subgroups and similar to those in the total RBX2660-treated population. A greater percentage of RBX2660-treated older adults remained free of CDI recurrence through 8 weeks following treatment compared with placebo-treated participants in all but 2 subgroups assessed. Across all subgroups, most treatment-emergent adverse events (TEAEs) were mild or moderate in severity and related to a preexisting condition. None of the serious or life-threatening TEAEs that occurred were related to RBX2660 or its administration. Occurrence of TEAEs did not cluster in any subgroup. Conclusions RBX2660 is efficacious and safe in older adults with recurrent CDI and underlying comorbidities.

[1]  S. Khanna,et al.  Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection , 2022, Drugs.

[2]  D. Gerding,et al.  Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial , 2022, BMC Infectious Diseases.

[3]  W. Nelson,et al.  Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults. , 2022, Journal of the American Medical Directors Association.

[4]  J. Wortman,et al.  SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. , 2022, The New England journal of medicine.

[5]  M. Charlson,et al.  Charlson Comorbidity Index: A Critical Review of Clinimetric Properties , 2022, Psychotherapy and Psychosomatics.

[6]  W. Nelson,et al.  Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with Clostridioides difficile infection with and without sepsis , 2021, Therapeutic advances in infectious disease.

[7]  K. Garey,et al.  Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  C. Kelly,et al.  ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections , 2021, The American journal of gastroenterology.

[9]  W. Nelson,et al.  Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis , 2021, Journal of managed care & specialty pharmacy.

[10]  Kimberly A. Reske,et al.  Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study , 2021, Genome Medicine.

[11]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. , 2021, Circulation.

[12]  W. Nelson,et al.  Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis , 2021, SAGE open medicine.

[13]  P. Greenberg,et al.  Association of Clostridioides difficile with adverse clinical outcomes in patients with acute diverticulitis: A nationwide study , 2020, Journal of gastroenterology and hepatology.

[14]  I. Kaur,et al.  Delivery routes for faecal microbiota transplants: Available, anticipated and aspired. , 2020, Pharmacological research.

[15]  Christopher V. Almario,et al.  Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms. , 2019, Gastroenterology.

[16]  R. Lynfield,et al.  Changes in Prevalence of Health Care–Associated Infections in U.S. Hospitals , 2018, The New England journal of medicine.

[17]  C. Hollenbeak,et al.  A Surgical Clostridium-Associated Risk of Death Score Predicts Mortality After Colectomy for Clostridium difficile , 2017, Diseases of the colon and rectum.

[18]  T. Buford.  (Dis)Trust your gut: the gut microbiome in age-related inflammation, health, and disease , 2017, Microbiome.

[19]  S. Linnebur,et al.  Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence , 2017, Therapeutic advances in drug safety.

[20]  Siddharth Singh,et al.  Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis , 2017, JAMA internal medicine.

[21]  E. Dubberke,et al.  Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach , 2016, BMC Infectious Diseases.

[22]  E. Dubberke,et al.  Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  G. Kaplan,et al.  Clostridium difficile associated risk of death score (CARDS): a novel severity score to predict mortality among hospitalised patients with C. difficile infection , 2016, Alimentary pharmacology & therapeutics.

[24]  J. Stausberg.  Epidemiology of clostridium difficile infection. , 2015, Deutsches Arzteblatt international.

[25]  D. Leffler,et al.  Clostridium difficile infection. , 2015, The New England journal of medicine.

[26]  Lisa G Winston,et al.  Burden of Clostridium difficile Infection in the United States , 2015 .

[27]  L. Valiquette,et al.  Risk Factors for Recurrence, Complications and Mortality in Clostridium difficile Infection: A Systematic Review , 2014, PloS one.

[28]  Christine Leong,et al.  Treatment Strategies for Recurrent Clostridium difficile Infection. , 2013, The Canadian journal of hospital pharmacy.

[29]  E. Gkrania-Klotsas,et al.  Risk factors for mortality in Clostridium difficile infection in the general hospital population: a systematic review. , 2012, The Journal of hospital infection.

[30]  Derrick W. Crook,et al.  Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  C. Kelly.  Can we identify patients at high risk of recurrent Clostridium difficile infection? , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[32]  Spyridon S Marinopoulos,et al.  The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. , 2008, Journal of clinical epidemiology.

[33]  Keith C. Norris,et al.  Chronic kidney disease in the United States: a public policy imperative. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[34]  I S Chan,et al.  Test‐Based Exact Confidence Intervals for the Difference of Two Binomial Proportions , 1999, Biometrics.

[35]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.